Medication company Viatris (NASDAQ: VTRS) fell short of the market’s revenue expectations in Q3 2026, with sales flat year on year at $3.75 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.8 billion at the midpoint. Its non-GAAP profit of $0.71 per share was 11.3% above analysts’ consensus estimates.
Is now the time to buy VTRS? Find out in our full research report (it’s free for active Edge members).
Viatris (VTRS) Q3 2026 highlights:
- Revenue $3.75 billion vs S&P analysts’ estimates of $3.80 billion (flat year on year, 1.3% miss)
- Adjusted EPS $0.71 vs S&P analysts’ estimates of $0.64 (11.3% beat)
- Adjusted EBITDA $1.20 billion vs analyst estimates of $1.13 billion (31.9% margin, 5.7% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $14.8 billion at the midpoint from $14.75 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $2.59 at the midpoint, a 3% increase
- EBITDA guidance $4.5 billion at the midpoint for the full year, above analyst estimates of $4.42 billion
- Operating margin 7%, up from 4.8% in the same quarter last year
- Market capitalization $21.79 billion
StockStory’s take
Viatris reported flat revenue growth in the latest quarter, falling slightly below Wall Street’s top-line expectations, but delivered a notable beat on adjusted profits and improved operating margin. Management credited strong demand in North America and Greater China for higher-margin products, particularly complex generics and estradiol patches. CEO Scott Smith highlighted the successful U.S. launch of new women’s health products and momentum in innovative medicines, while ongoing supply constraints in Europe and emerging markets tempered overall sales. The positive market reaction reflected confidence in the company’s execution and margin expansion.
Looking ahead, management expects continued growth from recently launched products, upcoming regulatory milestones, and the pending acquisition of Pacira BioSciences. CEO Scott Smith emphasized that the addition of Pacira’s portfolio will bolster Viatris’s U.S. innovative medicines business and expand its non-opioid pain management capabilities. Chief R&D Officer Philippe Martin pointed to late-stage pipeline progress, including fast-acting meloxicam and key phase III readouts expected in 2027, as important drivers of future performance. Management remains focused on navigating policy changes in China and mitigating supply chain headwinds while investing in capacity and product development.
Key insights from management’s remarks
Management attributed the quarter’s margin gains to a shift toward higher-value products in North America and China, while supply issues and regulatory changes affected certain geographies and segments.
- North America portfolio shift: Growth was driven by a move toward higher-margin complex generics and innovative medicines, with significant demand for estradiol patches and new injectable launches. The company is actively investing in expanded manufacturing capacity to meet rising U.S. demand.
- China market dynamics: Despite policy changes moderating growth in Chinese hospital channels, Viatris continued to see strong demand for its cardiovascular and established brands portfolios. Management noted that momentum is expected to continue as the company leverages its local affiliate and diversified channel investments.
- Product launch progress: The launch of Gwyn Lo, a low-dose contraceptive patch in the U.S., and regulatory approvals for RYZUMVI and WAKIX in key markets, were cited as milestones supporting growth. New launches are expected to diversify revenue streams and complement base business stability.
- Supply chain remediation: Ongoing supply constraints, notably at the Nashik manufacturing site, affected generic drug sales in Europe and emerging markets. Management is executing remediation and capacity expansion to resolve these disruptions and support future growth.
- Pacira acquisition strategy: The pending acquisition of Pacira BioSciences will add established non-opioid pain medicines and experienced commercial infrastructure in the U.S., positioning Viatris to accelerate its innovative medicine strategy and benefit from cost synergies and expanded R&D capabilities.
Drivers of future performance
Management’s outlook centers on expanding high-value product offerings, integrating new acquisitions, and addressing external supply and regulatory challenges.
- Capacity and product expansion: Ongoing investments in manufacturing and packaging will enable Viatris to meet rising demand for complex generics and women’s health products, especially estradiol patches. Management believes these actions will support margin improvement and revenue growth.
- Pacira integration and synergies: The addition of Pacira’s products, including EXPAREL and ZILRETTA, is expected to immediately enhance adjusted EBITDA and accelerate non-opioid pain management growth. Management anticipates over $50 million in annual cost synergies by 2028 and sees further opportunity to leverage Pacira’s U.S. commercial team for upcoming launches.
- Pipeline and regulatory milestones: Key phase III data readouts for selatogrel and cenerimod, plus regulatory decisions for fast-acting meloxicam and expanded indications for Creon, are set for 2027. Success in these programs could unlock new revenue streams and reinforce Viatris’s position in both specialty and generic markets.
Catalysts in upcoming quarters
In the quarters ahead, the StockStory team will watch (1) the successful close and integration of the Pacira acquisition and realization of synergies, (2) regulatory approvals and launch execution for fast-acting meloxicam and other late-stage pipeline assets, and (3) further resolution of supply chain issues, particularly at the Nashik facility. Additional attention will be paid to the evolving demand for women’s health products and policy impacts in China.
Viatris currently trades at $18.84, down from $19.22 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Stocks that trumped tariffs
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
